These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23982605)

  • 1. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
    Meniawy TM; Creaney J; Lake RA; Nowak AK
    Br J Cancer; 2013 Oct; 109(7):1813-20. PubMed ID: 23982605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
    Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
    In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
    Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
    Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB; Ozturk A; Mutlu H
    Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
    Yin W; Zheng G; Su S; Liang Y
    Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
    Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
    J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
    Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
    Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
    Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation-based prognostic indices in malignant pleural mesothelioma.
    Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
    J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
    Liu D; Jin J; Zhang L; Li L; Song J; Li W
    Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.
    Edwards JG; Abrams KR; Leverment JN; Spyt TJ; Waller DA; O'Byrne KJ
    Thorax; 2000 Sep; 55(9):731-5. PubMed ID: 10950889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of inflammatory parameters in the prognosis of malignant mesothelioma.
    Abakay O; Tanrikulu AC; Palanci Y; Abakay A
    J Int Med Res; 2014 Apr; 42(2):554-65. PubMed ID: 24573972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
    Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
    Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.